The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis

Current Opinion in Investigational Drugs

Volumn 10, Issue 8, 2009, Pages 787-794

  Sibley, Christopher D ^a   Parkins, Michael D ^a   Rabin, Harvey R ^a   Surette, Michael G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Antibacterial; Cystic fbrosis; Microbial community; Microbiome; Oropharyngeal flora; Pathogen; Polymicrobial; Pseudomonas aeroginosa; Pulmonary exacerbation; Streptococcus milleri group

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ARIKACE; AZITHROMYCIN; AZTREONAM LYSINATE; BAYQ 3939; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN PLUS TOBRAMYCIN; GS 9310 11; LEVOFLOXACIN; LIPOSOMAL AMIKACIN; MACROLIDE; MP 376; PLACEBO; TMB 100; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; GENETIC POLYMORPHISM; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; MIXED INFECTION; NONHUMAN; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 68649125562     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Sibley CD, Rabin H, Surette MG: Cystic fibrosis: A polymicrobial infectious disease. Future Microbiol (2006) 1(1):53-61.
2. Gilligan PH: Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev (1991) 4(1):35-51.
3. Foweraker J: Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br Med Bull (2009) 89(1):93-110.
4. Gibson RL, Burns JL, Ramsey BW: Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med (2003) 168(8):918-951.
5. McLaughlin FJ, Matthews WJ Jr, Strieder DJ, Sullivan B, Taneja A, Murphy P, Goldmann DA: Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: Ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis (1983) 147(3):559-567.
6. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL: Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: Lack of association in cystic fibrosis. Chest (2003) 123(5):1495-1502.
7. Moskowitz SM, Foster JM, Emerson J, Burns JL: Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (2004) 42(5):1915-1922.
8. Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL: Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother (2005) 56(5):879-886.
9. Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE: Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med (2000) 162(6):2241-2245.
10. Moskowitz S: Biofilm susceptibility testing: Does it have a role in CF microbiology? Pediatr Pulmonol (2008) 43 (S31): 159-160.
11. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox P, Yozghatlian V, Bye P et al: Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: A randomised, double-blind, controlled clinical trial. Lancet (2005) 366 (9484):463-471.
12. Foweraker JE, Laughton CR, Brown DF, Bilton D: Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother (2005) 55(6):921-927.
13. Foweraker JE: Reliability of antibiotic susceptibility testing in CF and relationship to clinical outcomes. Pediatr Pulmonol (2008) 43 (S31) :160-161.
14. Duan K, Dammel C, Stein J, Rabin H, Surette MG: Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol (2003) 50(5):1477- 1491. • Provided the first evidence for the relevance of the role of OF in CF.
15. Sibley CD, Duan K, Fischer C, Parkins MD, Storey DG, Rabin HR, Surette MG: Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog (2008) 4(10):e1000184. • The first demonstration that the OF in CF sputum are represented by a large proportion of potentially pathogenic isolates and organisms that can synergistically enhance the virulence of the principal pathogen in CF, P aeruginosa.
16. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG: A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA (2008) 105(39):15070-15075. •• Provided the first evidence that categorizing airway disease in CF as polymicrobial can have a clinical impact. This study demonstrated that the airway microbiome in CF can foster unrecognized pathogens, and specifically targeting such organisms can result in positive clinical outcomes.
17. Kolak M, Karpati F, Monstein HJ, Jonasson J: Molecular typing of the bacterial flora in sputum of cystic fibrosis patients. Int J Med Microbiol (2003) 293(4):309-317.
18. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD: Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol (2003) 41(8):3548-3558. • The first study to demonstrate that polymicrobial communities characteristically colonize in the airways in CF.
19. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD: Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol (2004) 42(11):5176- 5183.
20. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, Connett GJ, Bruce KD: Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol (2006) 44(7):2601-2604.
21. Gilljam H, Malmborg AS, Strandvik B: Conformity of bacterial growth in sputum and contamination free endobronchial samples in patients with cystic fibrosis. Thorax (1986) 41(8): 641-646.
22. Thomassen MJ, Klinger JD, Badger SJ, van Heeckeren DW, Stern RC: Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr (1984) 104(3):352-356.
23. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR: Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA (2007) 104(51):20529-20533. •• The largest culture-independent study to define the microbial constituents of human airways. Provided a comprehensive perspective on the complexity of the airway microbiome in CF.
24. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A, Elborn JS: Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med (2008) 177(9):995-1001. • Discusses the possibilities and necessity of exploring alternatives to the traditional practices for CF microbiology to improve the understanding of the microbial composition of the airways in CF.
25. Worlitzsch D, Rintelen C, Bohm K, Wollschlager B, Merkel N, Borneff-Lipp M, Doring G: Antibiotic-resistant obligate anaerobes during exacerbations of cystic brosis patients. Clin Microbiol Infect (2009) 15(5):454-46f0.
26. Brook I, Fink R: Transtracheal aspiration in pulmonary infection in children with cystic fibrosis. Eur J Respir Dis (1983) 64(1):51-57.
27. Jewes LA, Spencer RC: The incidence of anaerobes in the sputum of patients with cystic fibrosis. J Med Microbiol (1990) 31(4):271-274.
28. Appleman MD (Ed): Cumitech 43: Cystic Fibrosis Microbiology. American Society of Microbiology, Washington DC, USA (2006).
29. Hutchison ML, Govan JR: Pathogenicity of microbes associated with cystic fibrosis. Microbes Infect (1999) 1(12):1005-1014.
30. Lyczak JB, Cannon CL, Pier GB: Lung infections associated with cystic fibrosis. Clin Microbiol Rev (2002) 15(2):194-222.
31. Bittar F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremler N, Sarles J, Raoult D, Rolain JM: Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE (2008) 3(8):e2908.
32. Parkins MD, Sibley CD, Surette MG, Rabin HR: The Streptococcus milleri group - an unrecognized cause of disease in cystic fibrosis: A case series and literature review. Pediatr Pulmonol (2008) 43(5):490-497.
33. Cade A, Denton M, Brownlee KG, Todd N, Conway SP: Acute bronchopulmonary infection due to Streptococcus milleri in a child with cystic fibrosis. Arch Dis Child (1999) 80(3):278-279.
34. 1 in young adults with cystic fibrosis. Thorax (2006) 61(2): 155-157.
35. Gillham MI, Sundaram S, Laughton CR, Haworth CS, Bilton D, Foweraker JE: Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. J Antimicrob Chemother (2009) 63(4):728-732.
36. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R et al: Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. Am J Respir Crit Care Med (2007) 176(10):957-969.
37. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M: Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial. Lancet (2002) 360 (9338): 978-984.
38. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. J Am Med Assoc (2003) 290(13):1749-1756.
39. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J: Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial. Thorax (2002) 57(3):212-216.
40. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP: Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax (2006) 61(10):895-902. • Demonstrated that the beneficial effect of chronic azithromycin therapy can occur independently of P aeruginosa colonization.
41. Levert H, Gressier B, Moutard I, Brunet C, Dine T, Luyckx M, Cazin M, Cazin JC: Azithromycin impact on neutrophil oxidative metabolism depends on exposure time. Inflammation (1998) 22(2):191-201.
42. 3-stimulated THP-1 cells. Antimicrob Agents Chemother (1996) 40(6):1548-1551.
43. Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS: In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol (1995) 133(2):269-276.
44. Equi AC, Davies JC, Painter H, Hyde S, Bush A, Geddes DM, Alton EW: Exploring the mechanisms of macrolides in cystic fibrosis. Respir Med (2006) 100(4):687-697.
45. Wozniak DJ, Keyser R: Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest (2004) 125 (2 Suppl) :62S-69S.
46. Dupont MJ, Lapointe JR: Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to Pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin. J Antimicrob Chemother (1995) 36(1):231-236.
47. Mizukane R, Hirakata Y, Kaku M, Ishii Y, Furuya N, Ishida K, Koga H, Kohno S, Yamaguchi K: Comparative in vitro exoenzyme- suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1994) 38(3):528-533.
48. Yamasaki T, Ichimiya T, Hirai K, Hiramatsu K, Nasu M: Effect of antimicrobial agents on the piliation of Pseudomonas aeruginosa and adherence to mouse tracheal epithelium. J Chemother (1997) 9(1):32-37.
49. Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunaga T, Ohno A, Miyazaki S, Yamaguchi K: Direct evidence for antipseudomonal activity of macrolides: Exposuredependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother (1996) 40(10):2271-2275.
50. Ergin A, Ercis S, Hascelik G: Macrolide resistance mechanisms and in vitro susceptibility patterns of viridans group streptococci isolated from blood cultures. J Antimicrobhemother (2006) 57(1):139-141.
51. Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH: Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis (2002) 43(2):157-162.
52. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK: Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: Long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J (2007) 26(1):8-12.
53. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S et al: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med (1999) 340(1):23-30.
54. Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL et al: Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol (2006) 41(7):656-665.
55. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB: Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med (2008) 178(9):921-928.
56. Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL: A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol (2008) 43(1):47-58.
57. Dupont LJM, Fustik S, Mazurek H, Solyom E, Feketeova A, Csiszer E, Okusanya OO, Larsen EK, Gupta R: A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic brosis patients with chronic Pseudomonas aeruginosa lung infection. Pediatr Pulmonol (2008) 43 (S31) :301-302.
58. Wilson J, Moorehead L, Montgomery B: A phase 1 open label trial to assess the safety and tolerability of fosfomycin/tobramycin for inhalation (fti) in subjects with cystic fibrosis (cf) or bronchiectasis (be). Pediatr Pulmonol (2008) 43 (S31): 320-321.
59. MacLeod D, Velayudhan J, Kenney T, Therrien J, Baker W: GS-9310/11 mechanism of action: Enhanced inhibition of protein synthesis. Pediatr Pulmonol (2008) 43 (S31) :325.
60. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C: Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatr Pulmonol (2007) 42(4):307-313.
61. Stass HL, Nagelschmitz J, Staab D: Safety and pharmacokinetics of inhaled dry powder ciprofloxacin after single and multiple inhalations in patients with cystic fibrosis. Pediatr Pulmonol (2008) 43 (S31) :301-302.
62. Geller P, Schwab R, Fornos P, Conrad DJ, Morgan E, Griffith D, Lomovskaya O, Loutit J, Dudley M: A phase 1 safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients. Pediatr Pulmonol (2008) 43 (S31):315.